Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Oct 4;91(7):1263-8.
doi: 10.1038/sj.bjc.6602153.

Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study

C Allemani  1 , M Sant, F Berrino, T Aareleid, G Chaplain, J W Coebergh, M Colonna, P Contiero, A Danzon, M Federico, L Gafà, P Grosclaude, G Hédelin, J Macè-Lesech, C M Garcia, E Paci, N Raverdy, B Tretarre, E M I Williams
Affiliations

Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study

C Allemani et al. Br J Cancer. .

Abstract

We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990-1992 from cancer registries in Estonia, France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular plus mixed carcinoma, comedocarcinoma, 'special types', medullary carcinoma, not otherwise specified (NOS) carcinoma, other carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61-71) for NOS carcinoma to 95% (95% CI 90-100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27% (95% CI 18-36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age and stage at diagnosis.

PubMed Disclaimer

References

    1. Adami HO, Malker B, Holmberg L, Persson I, Stone B (1986) The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315: 559–563 - PubMed
    1. Chapman JA, Mobbs BG, Hanna WM, Sawka CA, Pritchard KI, Lickley HL, Trudeau ME, Ryan ED, Ooi TC, Sutherland DJ (1993) The standardization of estrogen receptors. J Steroid Biochem Mol Biol 45: 367–373 - PubMed
    1. Chapman JW, Mobbs BG, McCready DR, Lickley HL, Trudeau ME, Hanna W, Kahn HJ, Sawka CA, Fish EB, Pritchard KI (1996) An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. J Steroid Biochem Mol Biol 57: 323–328 - PubMed
    1. Chu KC, Anderson WF (2002) Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 74: 199–211 - PubMed
    1. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37–45 - PubMed

Publication types

Substances